Etodolac ext-rel Tablets Rx
Generic Name and Formulations:
Etodolac 400mg, 500mg, 600mg; ext rel tabs.
Various generic manufacturers
Indications for Etodolac ext-rel Tablets:
Osteoarthritis. Rheumatoid arthritis. Juvenile rheumatoid arthritis (JRA).
Use lowest effective dose for shortest duration. Initially 400–1000mg once daily.
<6yrs: not established. Use lowest effective dose for shortest duration. Give once daily. JRA: 6–16yrs (20–30kg): 400mg; (31–45kg): 600mg; (46–60kg): 800mg; (>60kg): 1000mg.
Aspirin allergy. Coronary artery bypass graft surgery.
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Discontinue if signs/symptoms of liver disease develop, or if abnormal LFTs persist or worsen. Advanced renal disease: not recommended. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic and renal function in long-term therapy. Pre-existing asthma. Discontinue at 1st sign of rash or any other hypersensitivity. Renal or hepatic impairment. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C; 3rd trimester: avoid). Nursing mothers: not recommended.
NSAID (pyranocarboxylic acid deriv.).
Avoid concomitant aspirin, salicylates, phenylbutazone, or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors, ARBs, or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. May cause false (+) urinary bilirubin test.
GI upset, dizziness, headache, rash (may be severe), anemia, edema, pruritus, tinnitus; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypersensitivity reactions.
Formerly known under the brand names Lodine (caps, tabs); Lodine XL (ext-rel tabs).
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Neuropathic Symptoms Worsen Quality of Life, Function in Hip, Knee Osteoarthritis
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- Switching From Buprenorphine-Naltrexone to XR-Naltrexone as Effective as XR-Naltrexone
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Human Diagnosis Project Aims to Address Challenges Among Uninsured
- Healthcare Technology Affects Younger Patient Satisfaction
- FDA Announces New Drug Shortages Task Force